× Key messages Background Findings Perspectives Expert commentary

Comparing long-term repeated use of M207 against the ZOTRIP trial

Key messages

  • The positive results from the phase 2b/3 single dose ZOTRIP trial were also seen in a long-term repeated-use study of M207 over 12 months.
  • M207 provided 44% pain freedom and 81% pain relief from migraine at 2 hours with repeated use, similar to the results reported in the ZOTRIP trial.
  • The pattern of adverse events (AEs) was similar to the ZOTRIP trial; nearly all mild and the most common were redness and swelling at the application site.